title: Manganese dipyridoxyl-diphosphate (MnDPDP) as a viability marker in patients with myocardial infarction.
abstract: OBJECTIVE
  To evaluate contrast accumulation in left ventricular (LV) myocardium after manganese dipyridoxyl-diphosphate (MnDPDP) administration in patients with recent first time myocardial infarction.
  
  
  METHODS
  MnDPDP (5 micromol/kg) was administered to 10 patients with recent myocardial infarction (three to 12 weeks). One slice of interest (SOI) likely to traverse the infarction was chosen, and sectorial pre- and postcontrast longitudinal relaxivity rates (R(1)) and signal changes during infusion were estimated with a fast gradient echo sequence. LV volume and wall thickening were measured in short-axis cine recordings. Infarct localization from R(1) and wall thickening data were compared by vector analyses.
  
  
  RESULTS
  Reduced wall thickening was associated with reduced precontrast R(1) and reduced contrast enhancement. Both remote and infarcted regions showed rapid initial contrast accumulation. In remote regions, this was followed by a continuing slow increase. Mean precontrast R(1) was 0.87 +/- 0.06 second(-1) in infarcted regions and 0.96 +/- 0.03 second(-1) in remote regions (P < 0.001). Mean R(1) change over one hour was 0.24 +/- 0.07 second(-1) in infarcted regions and 0.38 +/- 0.03 second(-1) in remote regions (P < 0.0001).
  
  
  CONCLUSIONS
  Remote regions showed larger increases in R(1) than infarcted regions. This is most likely due to selective and slow Mn accumulation in viable myocytes.
authors.affiliation: Department of Circulation and Medical Imaging (ISB), Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. Arne.Skjold@stolav.no
authors.forename: Arne
authors.initials: A
authors.lastname: Skjold
authors.forename: Brage H
authors.initials: BH
authors.lastname: Amundsen
authors.forename: Rune
authors.initials: R
authors.lastname: Wiseth
authors.forename: Asbjørn
authors.initials: A
authors.lastname: Støylen
authors.forename: Olav
authors.initials: O
authors.lastname: Haraldseth
authors.forename: Henrik B W
authors.initials: HB
authors.lastname: Larsson
authors.forename: Per
authors.initials: P
authors.lastname: Jynge
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000737:chemistry; D003287:Contrast Media / Q000494:pharmacology*; D003331:Coronary Vessels / Q000473:pathology; D004452:Echocardiography / Q000379:methods*; D004492:Edetic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D006352:Heart Ventricles / Q000473:pathology*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology*; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives* / Q000494:pharmacology; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D003287:Contrast Media; D011732:Pyridoxal Phosphate; D004492:Edetic Acid; C060076:N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid